Catabasis Pharmaceuticals Inc expected to post a loss of 30 cents a share - Earnings Preview

Astria Therapeutics

06/08/2021 23:50

* Catabasis Pharmaceuticals Inc  CATB.OQ   CATB.O  is expected
to show a no change in quarterly revenue when it reports
results on August 9 (estimated). 
​* Refinitiv's mean analyst estimate for Catabasis
Pharmaceuticals Inc is for a loss of 30 cents per share. For the
same quarter last year, the company reported a loss of 53 cents
per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts had risen by
about 14.8% in the last three months. ​
* Wall Street's median 12-month price target for Catabasis
Pharmaceuticals Inc is $5.5​, about 71.8% above​ its last
closing price of $1.55. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  -0.14       -0.15      -0.24     Missed  -56.5
 Dec. 31 2020  -0.34       -0.37      -0.44     Missed  -18.9
 Sep. 30 2020  -0.51       -0.51      -0.56     Missed  -9.8​
 Jun. 30 2020  -0.46       -0.45      -0.53     Missed  -16.5
 Mar.          -0.41​      -0.41      -0.50     Missed  -22​
 31​ 2020​                                              
 Dec. 31 2019  -0.56       -0.61      -0.55     Beat    10.6​
 Sep. 30 2019  -0.64       -0.64      -0.56     Beat    12
 Jun. 30 2019  -0.62       -0.61      -0.62     Missed  -2.2
 This summary was machine generated August 6 at 22:50 GMT.  All
figures in US dollars unless otherwise stated